Male-Specific Association between Dopamine Receptor D4 Gene Methylation and Schizophrenia

Jia Cheng1,2,*, Yunliang Wang3*, Kena Zhou1*, Lingyan Wang4*, Jinfeng Li3, Qidong Zhuang1, Xuting Xu1, Leiting Xu1, Kai Zhang1, Dongjun Dai1, Rongjiong Zheng1, Guangxue Li1,2, Aiping Zhang5, Shugui Gao2*, Shiwei Duan1*

1 Zhejiang Provincial Key Laboratory of Pathophysiology, School of Medicine, Ningbo University, Ningbo, Zhejiang, China, 2 Department of Psychiatry, Ningbo Kangning Hospital, Ningbo, Zhejiang, China, 3 Neurology Department of the 148th Hospital of PLA, Zibo, Shandong, China, 4 Bank of Blood Products, Ningbo No. 2 Hospital, Ningbo, Zhejiang, China, 5 Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders, Bio-X Institutes, Ministry of Education, Shanghai Jiao Tong University, Shanghai, China

Abstract

Objective: The goal of our study was to investigate whether DRD4 gene DNA methylation played an important role in the susceptibility of Han Chinese SCZ.

Methods: Using the bisulphite pyrosequencing technology, DNA methylation levels of 6 CpG dinucleotides in DRD4 CpG island were measured among 30 paranoid SCZ patients, 30 undifferentiated SCZ patients, and 30 age- and gender-matched healthy controls.

Results: Strong correlation was observed among the six CpG sites (r>0.5, p<0.01), thus average methylation levels were applied thereafter. Our results indicated that there was a significant association between DRD4 methylation and the risk of SCZ (P = 0.003), although there was no significant difference in DRD4 methylation between the two SCZ subtypes (P = 0.670). A breakdown analysis by gender showed that the significant association of DRD4 methylation and SCZ was driven by males (P<0.001) but not by females (P = 0.835). DRD4 methylation was significantly associated with p300 in male SCZ patients (r = −0.543, P = 0.005) but not in female SCZ patients (r = 0.110, P = 0.599). Moreover, receiver operating characteristic (ROC) curves showed DRD4 methylation was able to predict the status of SCZ in males [area under curve (AUC) = 0.832, P = 0.002] but not in females (AUC = 0.483, P = 0.876). Finally, a further expression experiment showed that DRD4 methylation in the gene body was positively associated with gene expression, although the exact mechanism of gene regulation remained unknown for this interesting DRD4 methylation.

Conclusion: The gender disparity in the DRD4 DNA methylation provides novel insights into the pathogenesis of SCZ.

Introduction

Schizophrenia (SCZ) is a complex mental disorder with a global lifetime prevalence of about 1% [1]. Paranoid SCZ and undifferentiated SCZ are two most common subtypes of SCZ according to DSM-IV criteria [2]. The hallmark symptoms of these subtypes comprise delusions, hallucinations, extremely disorganized behavior and negative symptoms [3]. SCZ is a complex disorder resulting from both genetic and environmental factors, including genetic vulnerability, neurotoxicity, unbalanced neurotransmitter, living environment, drug abuse and prenatal stressors [4,5,6]. Twin and family studies have revealed that SCZ is a heritable disorder [7,8], although heritability estimation varies due to the difficulty in separating the effects of genetics and environmental factors [9].

Dopamine (DA) is one of the most important neurotransmitters in human brain, and dysfunction of DA system is a fundamental event in SCZ development [10,11]. An inverted-U curve can describe the relationship between DA activity and cortical function, either up or down stimulation of DA can result in poor cerebral performance [12,10]. The dopamine receptor D4 (DRD4) is a subtype of dopamine receptor family that is activated by the DA [13]. The neuregulin and DA modulation of hippocampal function was dependent on DRD4 activation and genetically associated with SCZ [14]. It can regulate many neurological processes connecting with psychiatric disorders [15].
The variations of DRD4 were widely reported to be related to diverse human behavior phenotypes [16,17].

Epigenetic modification is one of the mechanisms underlying the interaction between environmental exposure and individual genetic background in the development of psychiatric disorders [18,19]. DNA methylation is a crucial way of epigenetic mechanisms that regulate expression of numerous functional genes in human nervous system [4,18,20]. However, there is a lack of epigenetic evidence for the involvement of DRD4 in SCZ pathogenesis.

The p300 wave, a component of an event-related potential, is often used as metrics of cognitive function and has been proved relative to SCZ cognitive impairment [10]. The p300 waveforms of monozygotic twins are almost the same and more unanimous than that in dizygotic twins [10,21]. This implied that p300 amplitude might be under genetic control and may serve as an endophenotype for SCZ [10]. In the present study, we explore the association between DRD4 methylation and SCZ clinical features such as cognitive symptomatology and medication. The goal of our study is to assess the association between DRD4 methylation and SCZ.

**Materials and Methods**

**Samples and clinical data**

The samples in the present study comprise 30 paranoid SCZ patients (15 males and 15 females), 30 undifferentiated SCZ patients (15 males and 15 females), and 30 healthy controls (15 males and 15 females). The details of their demographics and clinical information were shown in Table 1. SCZ patients were

| Characteristics                              | Mean ± SD | Range      | Men (n = 30) | Women (n = 30) | p value |
|----------------------------------------------|-----------|------------|--------------|----------------|---------|
| Age(year)                                    | 29.6 ± 5.4| [19–41]    | 29.8 ± 4.0   | 29.4 ± 6.6     | 0.686   |
| Occurrence age (year)                        | 21.6 ± 4.8| [12–33]    | 21.5 ± 4.9   | 21.7 ± 4.8     | 0.895   |
| Course of disease (year)                     | 8.0 ± 5.9 | [0.2–24.0] | 8.5 ± 5.6    | 7.6 ± 6.4      | 0.576   |
| Familial history (yes/no)                    | 16/44     | /          | 6/24         | 10.0/20        | /       |
| Mental trauma (yes/no)                       | 20/40     | /          | 7/23         | 13/17          | /       |
| Marriage (yes/no)                            | 20/40     | /          | 6/24         | 14/16          | /       |
| Smoking (yes/no)                             | 11/49     | /          | 11/19        | 0/30           | /       |
| Diagnostic types (paranoid/undifferentiated) | 30/30     | /          | 15/15        | 15/15          | /       |
| Outbreak form (chronic/sub-chronic/sub-acute/acute) | 16/33/3/8 | /          | 1/24/2/3     | 15/9/1/5       | /       |
| Cysteine (μmol/L)                            | 15.44 ± 12.88 | [5.50–64.20] | 17.98 ± 15.01 | 12.89 ± 9.95 | 0.156   |
| Mean methylation level (%)                   | 69.82 ± 16.76 | [28.00–94.20] | 71.87 ± 13.33 | 67.34 ± 15.82 | 0.210   |

doi:10.1371/journal.pone.0089128.t001

Figure 1. Significant methylation correlation of 6 CpG sites on DRD4 CpG islands**. a: The hg19 version from UCSC genome browser was used for the genomic positions.
doi:10.1371/journal.pone.0089128.g001
collected from Ningbo Kangning Hospital in Zhejiang province of China. Healthy controls were the volunteers in Ningbo Kangning Hospital. The mean age of SCZ patients was 29.6±5.4 years compared with 30.4±4.0 years for the control subjects. All patients were independently examined by at least two experienced psychiatrists (JC and SG). DSM-IV criteria and SCID-I were used for the diagnosis of SCZ patients. SCZ patients with history of serious or unstable medical illness were excluded from this study. Patients with other psychiatric co-morbidities and drug abuse were also excluded from current study. All SCZ subjects were previously pharmacologically treated by one type of antipsychotic drug. SCZ subjects were prescribed antipsychotic drugs for at least 8 weeks. Healthy controls were age- and gender-matched healthy persons without any history of psychiatric diseases or disorders, and serious diseases such as cancers and cardiac diseases. In addition, we performed a longitudinal study to research the effect of risperidone therapy on the DRD4 DNA methylation level in peripheral blood. Blood of five additional newly onset male patients were drawn before and after risperidone (3–6 mg/d) treatment as the main antipsychotic medication for 8 weeks. Chemistry Analyzer (AU2700, Olympus, Japan) was used for the measurement of cysteine at the Clinical Chemistry Laboratory of Ningbo Kangning Hospital. The study protocol was approved by the ethical committee of Ningbo University. The informed written consent was obtained from all subjects. The informed written consent of the participants, whose capacity to consent was compromised, were obtained from their guardians and the scientific work complies with the current laws of China.

Symptomatology assessments

A series of tests were used for symptomatology assessments. These tests comprised the Positive and Negative Syndrome Scale (PANSS), Clinical Global Impressions (CGI), Wisconsin Card Sorting Test, and Chinese version of Wechsler Memory Scale (WMS) test. As an endophenotype for evaluating the cognitive function, p300 wave was also recorded in this study and analyzed by two experienced psychiatrists (JC and SG) by using the neural electricity device (NDI-200P+, Shanghai, China).

DNA methylation assay

Human genomic DNA was prepared from peripheral blood samples using the nucleic acid extraction automatic analyzer (LabAid 820, Xiamen City, China). DNA was quantified using the PicoGreen® double strand (dsDNA) DNA Quantification Kit (Molecular Probes, Inc. Eugene, USA) and extracted from the fresh blood after being drawn from the involved individuals into a vacuum tube with 3.8% Sodium Citrate agent. Then the left blood and extracted DNA were stored at −80°C. As described previously [22,23], bisulphite pyrosequencing technology was used to determine methylation levels of 6 CpGs on the fragment within

**Figure 2. Male specific association of DRD4 methylation with the susceptibility of SCZ.**
doi:10.1371/journal.pone.0089128.g002

**Figure 3. No influence of smoking was found on DRD4 methylation in male SCZ subjects.**
doi:10.1371/journal.pone.0089128.g003

**Figure 4. Male specific correlation between DRD4 methylation and p300 in SCZ patients.**
doi:10.1371/journal.pone.0089128.g004
**DRD4** CpG island (Figure 1). PCR and pyrosequencing primers for **DRD4** gene amplification were described in Table S1. More details on the pyrosequencing assay are available in the study by Guay et al [24].

**Gene expression assay**

Total RNA was extracted from peripheral blood. RNA was extracted with TRIZOL reagent (Invitrogen Life Technologies Co, USA) according to the manufacturer’s protocol. RNA isolation and reverse transcription were described in our previous study [25]. Primers for qRT-PCR were designed according to the previous study [26]. The qRT-PCR reactions were conducted according to the previous workflow [25] under the thermal conditions reported before [26]. GAPDH was used as an endogenous control.

**Statistical analysis**

Categorical variables were compared using a Pearson chi-square test, whereas Student *t*-test was used to compare the mean group differences for continuous variables. A two-sided P-value < 0.05 was considered statistically significant. All statistical analyses were performed with PASW Statistics 18.0 software (SPSS, Inc., Somers, NY, USA).

**Results**

A total of 60 SCZ patients and 30 age- and gender-matched healthy controls are recruited in the current association study. The biological information of all SCZ subjects was shown in Table 1. In this study, we have selected a locus containing 6 CpG dinucleotides to explore the association of **DRD4** methylation with SCZ (Figure 1). We found DNA methylation levels were well correlated among all the CpGs (Figure 1, r = 0.5, P < 0.01), therefore average methylation was used to represent **DRD4** methylation in the following analyses. In addition, we didn’t observe any non-CpG methylation in the sequenced fragment.

No significant difference of methylation level was found between male (71.87 ± 13.33%) and female (67.34 ± 15.82%) SCZ patients (P = 0.210). Symptomatology assessments of 60 SCZ subjects were shown in Table S2. As shown in Figure S1, no significant difference of **DRD4** methylation was found between paranoid SCZ and undifferentiated SCZ in males (P = 0.906), females (P = 0.591) and combined groups (P = 0.670). Thus, we combined the SCZ subtypes in the following analyses. There was significant difference between SCZ patients (69.82 ± 16.76%) and healthy controls (62.92 ± 19.96%) in **DRD4** methylation (P < 0.001). As shown in Figure 2, a breakdown analysis by gender indicated there was significantly higher **DRD4** methylation in male SCZ patients comparing with healthy male controls (male cases versus male controls: 71.87 ± 13.33% versus 48.83 ± 16.79%, P < 0.001), however, no difference was observed between female SCZ patients (67.34 ± 15.92%) and female healthy controls (66.31 ± 12.30%, P = 0.835, Figure 2). Hypomethylation of **DRD4** was observed in the male controls (48.83 ± 16.79%) compared with the female controls (66.31 ± 12.30%, P < 0.05). There is no difference in **DRD4** methylation levels between smokers and non-smokers in male SCZ patients (P = 0.529, Figure 3). **DRD4** methylation was significantly inversely correlated with p300 in the male SCZ patients (Figure 4, r = -0.543, P = 0.005), but not in the female SCZ patients (Figure 4, r = 0.110, P = 0.599). Meanwhile, receiver operating characteristic (ROC) curve showed that **DRD4** methylation was able to predict the status of SCZ in males [Figure 5, area under curve (AUC) = 0.832, P = 0.002] but not in females (Figure 5, AUC = 0.483, P = 0.876).

---

**Figure 5. Male specific prediction of SCZ using **DRD4** methylation as a diagnostic marker.**

DOI:10.1371/journal.pone.0089128.g005

**Figure 6. **DRD4** methylation levels in male SCZ patients between before and after risperidone therapy.**

DOI:10.1371/journal.pone.0089128.g006

**Figure 7. Correlation of **DRD4** methylation levels with **DRD4** gene expression in the healthy males.**

DOI:10.1371/journal.pone.0089128.g007
An analysis by therapeutic antipsychotics showed that there were no significant differences in DRD4 methylation among SCZ patients with different drug treatment (Figure S2, P = 0.090). DRD4 methylation of subgrouped SCZ patients by therapeutic antipsychotics was significantly higher than that of healthy male controls (Figure S3, P<0.05), in contrast that no difference of DRD4 methylation was observed between female SCZ patients treated by clozapine and healthy female controls (Figure S3, P>0.05). To note, there were significant differences between medicated SCZ males on quetiapine and control males (Figure S3, P<0.001) and significant differences between medicated SCZ females on quetiapine and control females (Figure S3, P = 0.003), although both have equally small numbers of SCZ subjects (4 males and 5 females). Future work is needed to investigate the effect of quetiapine on DRD4 methylation in SCZ patients. A longitudinal research demonstrated there was no significant different DRD4 methylation between pre-therapy and post-therapy of risperidone in five additional male SCZ patients (Figure 6, P = 0.332).

In addition, we explored the result of combining the data of this five additional schizophrenic samples with other male controls, the result was accorded with Figure 2 (Figure S4, P<0.001). Furthermore, we have done an association analysis between cysteine levels and DRD4 methylation in both male and female SCZ subjects. The result showed no correlation between cysteine levels and DRD4 methylation in both genders of SCZ subjects (Figure S5, Female: r = −0.125, p = 0.509; Male: r = 0.293, p = 0.116). The p300 remained significant after excluding one male sample that was very different from others (Figure S6, Male: r = −0.427, p = 0.037).

In order to investigate the role of DRD4 methylation in the gene regulation, we further performed expression experiment among 10 male controls. Our results showed a significant positive correlation between DRD4 methylation and DRD4 gene expression in the healthy males (r = 0.713, P = 0.021, Figure 7). Our expression data suggests that DRD4 methylation is functionally relevant to expression level.

**Discussion**

SCZ is a type of complex disorder that is contributed by both genetic and environmental factors [27,28]. As reversible and inheritable modifications, epigenetic marks such as DNA methylation are important to reflect the interactions between genetic factors and environmental exposures, and thus may provide us novel understandings for the development of complex diseases or disorders [29,30].

DA transmitter plays an important role in the psychological function, and the DA receptors are involved in the neural signal pathway modulating human behavior [13,16]. The dopaminergic system is involved in many kinds of human behavioral performances, such as aggression, delinquency and other behavioural problems [16]. The dysregulation of DA system pathway was hypothesized to be one of major causes of SCZ [31]. Dopaminergic system was the biological targets of psycholytic drugs in SCZ treatment. Genetic variations of genes in this system can influence the response to antipsychotic treatment [10,17].

DRD4 gene encodes a subtype of DA receptor that regulates many neurological processes connecting with psychiatric disorders [15]. Genetic association of DRD4 gene has been reported in SCZ research [29,32,33]. However, the role of DRD4 methylation in SCZ development is not known yet. In the present study, we found that DRD4 was likely to exert its role in the susceptibility of male SCZ through its aberrant methylation. This finding may provide potential implication for future SCZ diagnosis and the development of personalized antipsychotic therapy.

Gender differences were observed in the onset and prevalence of SCZ [7]. Male patients have a 3-year younger age of onset and have 40% greater risk than the females [7]. Estrogenic protection may contribute to the prevention of SCZ onset in females [34], but the exact reason that causes this gender difference always puzzles SCZ researchers. The gender difference in the SCZ development suggested estrogen had a protective effect against SCZ [35]. Several dopaminergic system genes have been proved to contribute to the etiology of SCZ [36]. DRD4 may be a member of these susceptibility genes. A DRD4 variant was shown to be associated with gender-specific abnormal behaviors [16]. Higher exposure to psychosocial risk factors of male individuals may help explain this phenomenon [16]. In addition, we observed that DRD4 methylation was associated with p300 in males. However, no association was shown between DRD4 methylation and cytosine level. Our results revealed a male-specific DNA methylation of DRD4 gene and a positive correlation between DRD4 methylation and DRD4 expression in the healthy males. These findings may help to understand the gender disparity in SCZ development. It also indicates that the therapeutic schedule of SCZ needs to be prescribed in a gender-specific way.

There are several limitations in our study that need to be taken with caution. Firstly, DNA methylation levels change across different tissues [37]. Here we use the DRD4 methylation in peripheral blood as a surrogate of brain tissue. The aberrant blood DRD4 methylation in male SCZ patients may not imply an aberrant DRD4 methylation in their brain tissues. Secondly, due to the strict matching criteria for the methylation study, we only recruited 30 paranoid SCZ patients, 30 undifferentiated SCZ patients, and 30 age- and gender-matched healthy controls. Future validation with larger sample size is warranted in other ethnic populations. Thirdly, we didn’t investigate how a hypermethylation of DRD4 gene body activated gene expression. Future work will be needed to take this into account.

In summary, we found a gender dimorphism of DRD4 methylation in the susceptibility of SCZ. This epigenetic modification may give hints to elaborate the pathological mechanisms of SCZ, and provide new biological aspects of DRD4 gene. The aberrant methylation of DRD4 gene may be a valuable gender-specific biomarker to monitor the risk and development of SCZ.

**Supporting Information**

Table S1 Primers for DRD4 methylation analysis.
(DOC)

Table S2 Symptomatology assessments of 60 SCZ subjects in a series of tests.
(DOCX)

**Figure S1 Minimal difference of DRD4 methylation between the two subgrouped SCZ patients.**
(TIF)

**Figure S2 Stratification test by the antipsychotic medication in SCZ.**
(TIF)

**Figure S3 Breakdown analyses of stratification test by therapeutic antipsychotics.* * Only SCZ patients were on medication.**
(TIF)
Figure S4  Analysis of combining the data of these five additional schizophrenic samples with other male controls. (TIF)

Figure S5  Association analysis between cysteine levels and DRD4 methylation in both male and female SCZ subjects. (TIF)

References

1. Melas PA, Rogdaki M, Osby U, Schalling M, Lavebratt C, et al. (2012) Epigenetic aberrations in leukocytes of patients with schizophrenia: association of global DNA methylation with antipsychotic drug treatment and disease onset. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 26: 2712–2718.

2. Association AP (2000) Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR.

3. Fanous AH, Kendler KS (2008) Genetics of clinical features and subtypes of schizophrenia: a review of the recent literature. Curr Psychiatry Rep 10: 164–170.

4. Abdolmaleky HM, Yasghii S, Papageorgis P, Lembart AW, Ozurk S, et al. (2011) Epigenetic dysregulation of HTR2A in the brains of patients with schizophrenia and bipolar disorder. Schizophr Res 129: 183–190.

5. Gavin DP, Sharma RP (2010) Histone modifications, DNA methylation, and schizophrenia. Neurosci Biobehav Rev 34: 802–882.

6. Mellies N, Goldsacka M, Ginn E, Baker SP, Rossag E, et al. (2012) Gender-specific reduction of estrogen-sensitive small RNA, miR-30b, in subjects with schizophrenia. Schizophr Bull 38: 433–443.

7. Mulle JG (2012) Schizophrenia genetics: progress, at last. Curr Opin Genet Dev 22: 235–244.

8. Pchichoni MI, Murray RM (2007) Schizophrenia. BMJ (Clinical research ed.) 335: 91–95.

9. O’Donovan MC, Williams NM, Owen MJ (2005) Recent advances in the genetics of schizophrenia. Hum Mol Genet 12 Spec No 2: R215–R233.

10. Gao S, Hu Z, Cheng J, Zhou W, Xu Y, et al. (2012) Impact of catechol-O-methyltransferase polymorphisms on risperidone treatment for schizophrenia. Mol Psychiatry 17: 1194–1205.

11. Prata DP, Mechelli A, Fu CH, Pchichoni M, Kane F, et al. (2009) Opposite effects of catechol-O-methyltransferase Val108Met polymorphism on cortical function in healthy subjects and patients with schizophrenia. Biol Psychiatry 65: 473–480.

12. Barrett JH, Sorens L, Munafo MR (2008) Meta-analysis of the cognitive effects of the catechol-O-methyltransferase Val108Met polymorphism. Biol Psychiatry 64: 137–144.

13. Van Tol HH, Bunzon JR, Guan HC, Sumahara RK, Seeman P, et al. (1991) Cloning of the gene for a human dopamine D4 receptor with high affinity and high selectivity. Soc Cogn Affect Neurosci 6: 82–89.

14. Anderson RH, Johnston A, Herman PA, Winzer-Serhan UH, Karavanova I, et al. (2012) Neuregulin and dopamine modulation of hippocampal gamma oscillations is dependent on dopamine D4 receptors. Proc Natl Acad Sci U S A 109: 13118–13123.

15. Paclik R, Kazolova H, Stefanova GB (2011) Dopamine D4 receptor gene DRD4 and its association with psychiatric disorders. Medical science monitor : international medical journal of experimental and clinical research 17: RA215–220.

16. Dmitrieva J, Chen G, Greenberger E, Ogunesan O, Ding YC (2011) Gender-specific expression of the DRD4 gene on adolescent delinquency, anger and thrill seeking. Soc Cogn Affect Neurosci 6: 82–89.

17. Zai CC, Twari AK, Basile V, De Luca V, Muller DJ, et al. (2009) Association study of tardive dyskinesia and five DRD4 polymorphisms in schizophrenia patients. Pharmacogenomics 9: 168–174.

18. Eklstrom TJ, Lavebratt C, Schalling M (2012) The importance of epigenomic studies in schizophrenia. Epigenomics 4: 359–362.

19. Dong E, Nelson M, Grayson DR, Costa E, Guidotti A (2000) Clozapine and sulpiride but not haloperidol or olanzapine activate brain DNA demethylation. Proc Natl Acad Sci U S A 105: 15614–15618.

20. Mill J, Tang T, Kaminsky Z, Khare T, Yazdanpanah S, et al. (2008) Epigenomic profiling reveals DNA-methylation changes associated with major psychosis. Am J Hum Genet 82: 696–711.

21. Bestelmeyer PE, Phillips LH, Croome C, Benson P, St Clair D (2009) The P300 as a possible endophenotype for schizophrenia and bipolar disorder: Evidence from twin and patient studies. Psychiatry Res 169: 212–219.

22. Zhong LN, Lin P, Wang L, Yuan F, Xu L, et al. (2013) Lower ADH1 gene promoter DNA methylation increases the risk of essential hypertension. PLoS One 8: e63355.

23. Jiang D, Zheng D, Wang L, Huang Y, Liu H, et al. (2013) Elevated PLA2G7 gene promoter methylation as a gender-specific marker of aging increases the risk of coronary heart disease in females. PLoS One 8: e69752.

24. Guay SP, Brison D, Munger J, Lamarbe B, Gaudet D, et al. (2012) ABCA1 gene promoter DNA methylation is associated with HDL particle profile and coronary artery disease in familial hypercholesterolemia. Epigenetics 7: 464–472.

25. Chen C, Wang L, Liao Q, Huang Y, Ye H, et al. (2013) Hypermethylation of EDRNRB promoter contributes to the risk of colorectal cancer. Diagn Pathol 8: 199.

26. Bondy B, de Jonge S, Pander S, Prins J, Akenheil M (1996) Identification of dopamine D4 receptor mRNA in circulating human lymphocytes using nested polymerase chain reaction. J Neuroimmunol 71: 139–144.

27. Schmidt-Kasner R, van Os J, Espinel G, Steinbusch HW, Rutter BP (2012) An environmental analysis of genes associated with schizophrenia: hypoxia and vascular factors as interacting elements in the neurodevelopmental model. Mol Psychiatry 17: 1194–1205.

28. Docherty JM (2008) Epigenetic mechanisms as mediators of environmental risks for psychiatric disorders. Psychiatry 7: 500–506.

29. Docherty SJ, Davis OS, Haworth CM, Plomin R, D’Souza U, et al. (2012) A genetic association study of DNA methylation levels in the DRD4 gene region finds associations with nearby SNPs. Behav Brain Funct 8: 31.

30. Stahl SM (2010) Focusing mother nature: epigenetics and novel treatments for psychiatric disorders. CNS Spectr 15: 358–365.

31. Lee KY, Joo EJ, Yi YI, Kim DH, Park JB, et al. (2011) Associations between DRDs and schizophrenia in a Korean population: multi-stage association analyses. Exp Mol Med 43: 44–52.

32. Okuyama Y, Ishiguro H, Toru M, Arinami T (1999) A genetic polymorphism in the promoter region of DRD4 associated with expression and schizophrenia. Proc Soc Exp Biol Med 221: 292–295.

33. Pal P, Mihanovic M, Molnar S, Xi H, Sun G, et al. (2009) Association of tagging single nucleotide polymorphisms on 8 candidate genes in dopaminergic pathway with schizophrenia in Chinese population. Genet Mol Med 5: 361–369.

34. Lindauer LA, Lohe JB, Harris MJ, Jeste DV (1997) Gender, estrogen, and schizophrenia. Psychopharmacol Bull 33: 221–228.

35. Grigoriadis S, Seeman MV (2008) The role of estrogen in schizophrenia: implications for schizophrenia practice guidelines for women. Can J Psychiatry 53: 437–442.

36. Roth TL, Lubin FD, Sodhi M, Kleinman JE (2009) Epigenetic mechanisms in schizophrenia. Biochim Biophys Acta 1790: 869–877.

37. Pinouneault J, Sadre W (2003) Pharmacogenomics of multigenic diseases: sex-specific differences in disease and treatment outcome. AAPS pharm Sci 5(4): E29.